Medincell SA
PAR:MEDCL
Gross Margin
Medincell SA
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| FR |
|
Medincell SA
PAR:MEDCL
|
431.9m EUR |
92%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
685.8B USD |
81%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
362.5B USD |
69%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
85%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
196.2B CHF |
73%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
176.4B CHF |
75%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
205.6B USD |
81%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
155.9B GBP |
82%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
162.4B USD |
68%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
128.2B USD |
74%
|
Medincell SA
Glance View
MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. The company is headquartered in Jacou, Occitanie and currently employs 150 full-time employees. The company went IPO on 2018-10-08. The firm is focused on the development of therapeutic solutions with worldwide access. The firm works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Medincell SA's most recent financial statements, the company has Gross Margin of 91.6%.
You don't have any saved screeners yet